69 Views | 43 Downloads
Flavia Pichiorri
Department of Hematologic Malignancies Translational Science, City of Hope, 1500 E. Duarte Rd., Duarte, CA 91010.
Phone: 626-218-4908
Amrita Krishnan
Department of Hematology and Hematopoietic Cell Transplantation, City of Hope, Duarte, CA 91010.
Phone: 626-218-2405
Author contributions: DV, AD, SJF, PJY, JJK, JS, STR, CCH, GM, AK, and FP designed research; DV, AD, MM, EGG, ET, EC, FB, X Wu, JK, TM, ST, CK, MH, MR, DS, RRM, TE performed research; DV, AV, LG, JFS, X Wang analyzed data; AD, JFS, AK and FP wrote the manuscript; all authors reviewed the manuscript.
We thank Dori Triplet, Evelyn Flores, Elizabeth Hartman and Debbie Flood for administrative support. We also thank Suzan King and Steve Allen for their support.
Competing interests: AK is a consultant for Celgene and Janssen, serves on the speakers’ bureau for SutroBioPharma, zPredicta, Celgene, Amgen, and Takeda, and has stock ownership in Celgene. CCH has received research grants from Takeda & Oncolytics Biotech; research and personal grants from Janssen, BMS, Sanofi, Nektar, and Karyopharm; and personal grants from Imbrium Pharmaceuticals and Oncopeptides, all outside the submitted work.
Research was in part supported by the National Institute of Health under grant number NIH-2-R01-CA201382(FP, CCH) and in part under the NIH-2-R01-CA238429-01 (FP, JS, XW) and in part by the Steven Gordon and Briskin Family Innovation Grant. Research reported in this publication included work performed at the Liquid Tissue Bank, Analytical Cytometry, and Integrative Genomics and Bioinformatics shared resource cores supported by the National Institutes of Health under award number P30CA033572. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health.
2020